BCMLT
CTMX icon

Beacon Capital Management LLC (Tennessee)’s CytomX Therapeutics CTMX Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,000
Closed -$7.55K – 1030
2023
Q1 		$7.55K Hold
5,000
– – ﹤0.01% 555
2022
Q4 		$8K Hold
5,000
– – ﹤0.01% 551
2022
Q3 		$9K Buy
+5,000
New +$7.7K ﹤0.01% 489

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s CTMX Position: Q2 2023 in Review

Beacon Capital Management LLC (Tennessee) sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 5,000 shares — an estimated $7.55K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in CTMX in Q3 2022 and held it in 3 quarters. The position peaked at $9K in Q3 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

  • Beacon Capital Management LLC (Tennessee) reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 5,000 CytomX Therapeutics shares in Q2 2023, an estimated $7.55K.
  • Beacon Capital Management LLC (Tennessee) first reported a position in CytomX Therapeutics in Q3 2022 and held it in 3 quarters.
  • Beacon Capital Management LLC (Tennessee)'s CytomX Therapeutics position peaked at $9K in Q3 2022.
  • 67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q2 2023, filed 12 Jul 2023.